{"id":"NCT00686920","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy","officialTitle":"A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03-07","primaryCompletion":"2010-12-08","completion":"2010-12-08","firstPosted":"2008-05-30","resultsPosted":"2019-08-14","lastUpdate":"2019-08-14"},"enrollment":322,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatic Encephalopathy"],"interventions":[{"type":"DRUG","name":"Rifaximin","otherNames":["XifaxanÂ®"]}],"arms":[{"label":"Rifaximin","type":"EXPERIMENTAL"}],"summary":"This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.","primaryOutcome":{"measure":"Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event","timeFrame":"Baseline up to Month 36","effectByArm":[{"arm":"New Rifaximin","deltaMin":78,"sd":null},{"arm":"Continuing Rifaximin","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":35,"countries":["United States","Canada"]},"refs":{"pmids":["37467180","24365449"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":158,"n":252},"commonTop":["Nausea","Urinary tract infection","Oedema peripheral","Hypokalaemia","Ascites"]}}